Psychotic Disorders
Conditions
Brief summary
The broad goals of our pilot study are to (1) determine whether psychodynamic psychotherapy for psychosis (PPfP), relative to treatment as usual (TaU), can maintain or augment clinical and functional benefits for patients who have achieved initial recovery in our coordinated specialty care (CSC) early psychosis treatment program; (2) to conduct novel empirical study of how various psychodynamic factors may inform candidate selection, mediate therapeutic effects, and influence relational aspects of the therapy; and (3) to conduct a detailed study of how features of therapist and patient speech and behavior influence therapeutic outcomes, therapeutic alliance alliance, and relational process. This registration focuses on the first goal.
Interventions
BEHAVIORALPsychodynamic Psychotherapy
Intensive psychotherapy that is psychodynamically oriented.
BEHAVIORALUsual Care
Conventional treatment offered in the community.
Sponsors
University of Southern California
American Psychoanalytic Association
Yale University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* completed the 2-3 year Coordinated Specialty Care (CSC) program * judged by present provider to be in an intermediate or advanced phase of recovery * had first episode of psychosis within the 3 years prior to enrollment
Exclusion criteria
* established diagnosis of primary affective disorder, psychosis secondary to substance use or a medical illness * inability to communicate in English * eligibility for Department of Developmental Services * legally mandated to enter treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Functioning - Social | From enrollment up to 5 years from enrollment. | The Global Functioning: Social scale will be used, with symptoms rated 1 (most impaired) to 10 (superior functioning). |
| Overall Functioning - Role | From enrollment up to 5 years from enrollment. | The Global Functioning: Role scale will be used, with symptoms rated 1 (most impaired) to 10 (superior functioning). |
| Overall Symptom Severity | From enrollment up to 5 years from enrollment. | The Positive and Negative Symptom Scale (PANSS) will be used. This is a 30 item scale. Each item is measured on a 7-point scale from 1 (absent) to 7 (extreme). Items are summed to obtain an overall score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Symptom Severity (Positive Symptoms) | From enrollment up to 5 years from enrollment. | The positive symptoms subscale of the Positive and Negative Symptom Scale (PANSS) will be used. Each item is measured on a 7-point scale from 1 (absent) to 7 (extreme). Subscale items are summed to obtain a positive symptom score. |
| Symptom Severity (Negative Symptoms) | From enrollment up to 5 years from enrollment. | The negative symptoms subscale of the Positive and Negative Symptom Scale (PANSS) will be used. Each item is measured on a 7-point scale from 1 (absent) to 7 (extreme). Subscale items are summed to obtain an overall score. |
Outcome results
None listed